sag Search Results


95
MedChemExpress agonist
Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/agonist/product/MedChemExpress
Average 95 stars, based on 1 article reviews
agonist - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

sag  (Tocris)
95
Tocris sag
Sag, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sag/product/Tocris
Average 95 stars, based on 1 article reviews
sag - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

94
Tocris sag 21k
A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist <t>21K</t> (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.
Sag 21k, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sag 21k/product/Tocris
Average 94 stars, based on 1 article reviews
sag 21k - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Tocris shh agonist sag 21k
A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist <t>21K</t> (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.
Shh Agonist Sag 21k, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shh agonist sag 21k/product/Tocris
Average 94 stars, based on 1 article reviews
shh agonist sag 21k - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Selleck Chemicals s7779
A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist <t>21K</t> (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.
S7779, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s7779/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
s7779 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology hbsag
A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist <t>21K</t> (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.
Hbsag, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbsag/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
hbsag - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

96
Tocris smoothend agonist sag dihydrochloride
A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist <t>21K</t> (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.
Smoothend Agonist Sag Dihydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/smoothend agonist sag dihydrochloride/product/Tocris
Average 96 stars, based on 1 article reviews
smoothend agonist sag dihydrochloride - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

91
Biogems International dopa2 medium
Protocol for differentiation and encapsulation of DA neurons. (A) Protocol for expansion of DA neural progenitors and final differentiation of DA neurons. (B) Representative phase-contrast images of DOPA1, <t>DOPA2,</t> and DOPA3 cells. Scale bar: 100 μm. (C) Timeline for encapsulation within SAPNS. DA, dopaminergic; SAPNS, self-assembling peptide nanofiber scaffolds. Color images are available online.
Dopa2 Medium, supplied by Biogems International, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dopa2 medium/product/Biogems International
Average 91 stars, based on 1 article reviews
dopa2 medium - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier

90
Biosynth Carbosynth abz ala gly leu ala p nitro benzyl amide
Protocol for differentiation and encapsulation of DA neurons. (A) Protocol for expansion of DA neural progenitors and final differentiation of DA neurons. (B) Representative phase-contrast images of DOPA1, <t>DOPA2,</t> and DOPA3 cells. Scale bar: 100 μm. (C) Timeline for encapsulation within SAPNS. DA, dopaminergic; SAPNS, self-assembling peptide nanofiber scaffolds. Color images are available online.
Abz Ala Gly Leu Ala P Nitro Benzyl Amide, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abz ala gly leu ala p nitro benzyl amide/product/Biosynth Carbosynth
Average 90 stars, based on 1 article reviews
abz ala gly leu ala p nitro benzyl amide - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sag
Protocol for differentiation and encapsulation of DA neurons. (A) Protocol for expansion of DA neural progenitors and final differentiation of DA neurons. (B) Representative phase-contrast images of DOPA1, <t>DOPA2,</t> and DOPA3 cells. Scale bar: 100 μm. (C) Timeline for encapsulation within SAPNS. DA, dopaminergic; SAPNS, self-assembling peptide nanofiber scaffolds. Color images are available online.
Sag, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sag/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
sag - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

93
Tocris sag dihydrochloride
Reagents and tools table
Sag Dihydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sag dihydrochloride/product/Tocris
Average 93 stars, based on 1 article reviews
sag dihydrochloride - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.

Journal: bioRxiv

Article Title: Two parallel lineage-committed progenitors contribute to the developing brain

doi: 10.1101/2025.07.02.662771

Figure Lengend Snippet: A) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with Vismodegib + PD173074 for 72 hours, in the presence or absence of WNT agonist (CHIR99021, 1-6 μM) or WNT inhibitor (XAV939, 1 μM). This revealed that 2 μM of CHIR99021 (indicated by white circle) was optimal for inducing dorsal forebrain marker EMX2 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . HH inh.: HEDGEHOG inhibitor. FGFR inh.: FGF receptor inhibitor. B) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of FGF2 (20 ng/mL) or FGFR inhibitor (PD173074, 100 nM). This revealed that FGF inhibition enhanced dorsal forebrain markers EMX2 and PAX6 , while preventing erroneous WNT-induced expression of midbrain marker EN1 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . FGFRi: FGF receptor inhibitor. C) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with CHIR99021 (2 μM) + PD173074 (100 nM) for 72 hours, in the presence or absence of BMP4 (10 ng/mL) or BMPR inhibitors (DMH1 [250 nM] or LDN193189 [100 nM]). Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. D) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then anterior neural ectoderm within 24 hours, followed by forebrain progenitors within 48 hours. Forebrain progenitors were then treated with XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (0.1-5 nM) for 72 hours to generate ventral forebrain. This showed that high HEDGEHOG pathway activation, together with WNT inhibition, led to maximum expression of ventral forebrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. HH: Hedgehog pathway agonist. WNTi: WNT inhibitor. E) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG inhibitor (Vismodegib, 150 nM) and WNT agonist (CHIR99021, 2 μM) for 72 hours to generate dorsal forebrain, in the presence or absence of BMP agonist (BMP4, 10 ng/mL) or BMPR inhibitor (LDN193189, 100 nM). This showed that BMP inhibition promoted expression of dorsal forebrain markers GSX2 and PAX3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. F) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with HEDGEHOG pathway inhibitor Vismodegib (150 nM) in the presence or absence of increasing doses of WNT pathway agonist CHIR99021 (1-4 μM) for 72 hours to generate dorsal forebrain. This showed that moderate WNT pathway activation, together with HH inhibition, led to maximum expression of dorsal hindbrain markers GSX2 and OLIG3 . Gene expression is shown relative to reference gene YWHAZ ; 100% indicates that a gene is expressed at the same level as YWHAZ . BMPRi: BMP receptor inhibitor. G) scRNAseq of H7 hPSC-derived day-4 hindbrain progenitors, and day-7 dorsal hindbrain or ventral hindbrain progenitors. Colors denote differentiation conditions. An asterisk (*) indicates that the legend is identical to that shown in , and is reproduced here to aid the interpretation of other images shown in this subpanel. H) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with either Vismodegib (150 nM) + CHIR99021 (2 μM) + DMH1 (250 nM) for 72 hours to generate dorsal forebrain, or alternatively, 21K (5 nM) + XAV939 (1 μM) for 72 hours to generate ventral forebrain. Gene expression is shown relative to the sample with the highest expression in this experiment. I) H1 hPSCs were differentiated into definitive ectoderm within 24 hours, and then posterior neural ectoderm within 24 hours, followed by hindbrain progenitors within 48 hours. Hindbrain progenitors were then treated with WNT pathway inhibitor XAV939 (1 μM) in the presence or absence of increasing doses of HEDGEHOG pathway agonist 21K (50 pM-5 nM) for 72 hours to generate ventral hindbrain. This showed that high doses of HEDGEHOG agonist, together with WNT inhibitor, were required to maximally induce ventral hindbrain markers. Gene expression is shown relative to the sample with the highest expression in this experiment. WNT inh.: WNT inhibitor. qPCR data depicts the mean of two biological replicates, with s.e.m. shown. In vitro scRNAseq data is from a single experiment.

Article Snippet: D5, D6, and D7 dorsal forebrain media consisted of CDM2 supplemented with XAV939 (1 μM, Tocris) and SAG 21K (5 nM, Tocris).

Techniques: Marker, Gene Expression, Inhibition, Expressing, Activation Assay, Derivative Assay, In Vitro

Protocol for differentiation and encapsulation of DA neurons. (A) Protocol for expansion of DA neural progenitors and final differentiation of DA neurons. (B) Representative phase-contrast images of DOPA1, DOPA2, and DOPA3 cells. Scale bar: 100 μm. (C) Timeline for encapsulation within SAPNS. DA, dopaminergic; SAPNS, self-assembling peptide nanofiber scaffolds. Color images are available online.

Journal: Tissue Engineering. Part A

Article Title: Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons

doi: 10.1089/ten.tea.2019.0094

Figure Lengend Snippet: Protocol for differentiation and encapsulation of DA neurons. (A) Protocol for expansion of DA neural progenitors and final differentiation of DA neurons. (B) Representative phase-contrast images of DOPA1, DOPA2, and DOPA3 cells. Scale bar: 100 μm. (C) Timeline for encapsulation within SAPNS. DA, dopaminergic; SAPNS, self-assembling peptide nanofiber scaffolds. Color images are available online.

Article Snippet: Twenty-four hours later, neurospheres were plated onto a six-well tissue culture polystyrene (TCPS) dish (Eppendorf) ( Supplementary Figure S2 ) coated with 5 μg/mL laminin (MilliporeSigma), in DOPA2 medium (base medium supplemented with 0.5 μM SAG [9128694; Biogems]), 5 μM Y-27632, and 10 ng/mL of the following growth factors (PeproTech): stromal cell-derived factor 1-alpha (SDF-1α); Pleiotrophin; hepatocyte growth factor (HGF); insulin-like growth factor-2 (IGF-2); vascular endothelial growth factor-D (VEGF-D); secreted frizzled-related protein 1 (SFRP-1), fibroblast growth factor-8 (FGF-8); and 20 ng/mL cerebral dopamine neurotrophic factor (CDNF).

Techniques:

Characterization of DA neural progenitors and DA neurons. (A) Immunocytochemical staining of the following markers: Nestin: neural stem/progenitor, Tuj1 (β-III tubulin): neuron, MAP2: mature neuron, TH: DA neuron, Ki-67: proliferative cells, Synapsin: synaptic vesicle, FOXA2: midbrain DA neuron, PITX3: midbrain DA neuron, En-1 (Engrailed-1): midbrain DA neuron, DAPI: nucleus. Scale bar: 50 μm. (B) qRT-PCR analysis comparing gene expression in 2D and 3D (SAPNS-encapsulated) DA neurons at day 22 of differentiation. Data are presented as log2 of the fold change in expression relative to DOPA2 neural progenitors, shown in a bar graph (left) and heat map (right). Error bars represent standard deviation. p > 0.05, Student's unpaired t-test. 2D, two-dimensional; 3D, three-dimensional; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; TH, tyrosine hydroxylase. Color images are available online.

Journal: Tissue Engineering. Part A

Article Title: Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons

doi: 10.1089/ten.tea.2019.0094

Figure Lengend Snippet: Characterization of DA neural progenitors and DA neurons. (A) Immunocytochemical staining of the following markers: Nestin: neural stem/progenitor, Tuj1 (β-III tubulin): neuron, MAP2: mature neuron, TH: DA neuron, Ki-67: proliferative cells, Synapsin: synaptic vesicle, FOXA2: midbrain DA neuron, PITX3: midbrain DA neuron, En-1 (Engrailed-1): midbrain DA neuron, DAPI: nucleus. Scale bar: 50 μm. (B) qRT-PCR analysis comparing gene expression in 2D and 3D (SAPNS-encapsulated) DA neurons at day 22 of differentiation. Data are presented as log2 of the fold change in expression relative to DOPA2 neural progenitors, shown in a bar graph (left) and heat map (right). Error bars represent standard deviation. p > 0.05, Student's unpaired t-test. 2D, two-dimensional; 3D, three-dimensional; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; TH, tyrosine hydroxylase. Color images are available online.

Article Snippet: Twenty-four hours later, neurospheres were plated onto a six-well tissue culture polystyrene (TCPS) dish (Eppendorf) ( Supplementary Figure S2 ) coated with 5 μg/mL laminin (MilliporeSigma), in DOPA2 medium (base medium supplemented with 0.5 μM SAG [9128694; Biogems]), 5 μM Y-27632, and 10 ng/mL of the following growth factors (PeproTech): stromal cell-derived factor 1-alpha (SDF-1α); Pleiotrophin; hepatocyte growth factor (HGF); insulin-like growth factor-2 (IGF-2); vascular endothelial growth factor-D (VEGF-D); secreted frizzled-related protein 1 (SFRP-1), fibroblast growth factor-8 (FGF-8); and 20 ng/mL cerebral dopamine neurotrophic factor (CDNF).

Techniques: Staining, Quantitative RT-PCR, Expressing, Standard Deviation, Reverse Transcription Polymerase Chain Reaction

Reagents and tools table

Journal: The EMBO Journal

Article Title: Somatostatin triggers local cAMP and Ca 2+ signaling in primary cilia to modulate pancreatic β-cell function

doi: 10.1038/s44318-025-00383-7

Figure Lengend Snippet: Reagents and tools table

Article Snippet: SAG dihydrochloride , Tocris , 6390.

Techniques: Recombinant, Plasmid Preparation, Sequencing, Virus, Cloning, Modification, Software, Microscopy, Real-time Polymerase Chain Reaction, SYBR Green Assay, Ligation